Print this page    •   Back to Web version of article

GSK572 Integrase Inhibitor Shines In Phase II

By Liz Highleyman

Summer/Fall 2010

S/GSK1349572 -- or GSK572 for short -- is a second-generation integrase inhibitor being developed jointly by Shionogi and ViiV Healthcare. Prior research has shown that it works against HIV with some raltegravir-resistance mutations and has a high genetic barrier to resistance. According to data from two Phase IIb trials presented at AIDS 2010, the drug continues to demonstrate potent antiviral activity and good tolerability.

The SPRING-1 study (abstract THLBB205) included 205 previously untreated HIV patients. Most were men, 80% were white, and the median baseline CD4 cell count was 324 cells/mm3. Participants were randomly assigned to receive GSK572 at doses of 10 mg, 25 mg, or 50 mg, or else 600 mg efavirenz once-daily. About two-thirds took tenofovir/emtricitabine and one-third took abacavir/lamivudine as an NRTI backbone.

In a planned 16-week interim analysis, GSK572 demonstrated "rapid and robust" antiviral activity, with at least 90% of participants in all three dose arms reaching undetectable HIV RNA (below 50 copies/mL), compared with 60% in the efavirenz arm. Patients using GSK572 also took significantly less time to achieve viral suppression. CD4 cell gains ranged from 153 to 176 cells/mm3 in the GSK572 arms, compared with 116 cells/mm3 in the efavirenz arm.

GSK572 was generally well-tolerated; only 4%-8% of participants in the GSK572 arms experienced at least moderate drug-related adverse events, compared with 18% in the efavirenz arm.

VIKING was a smaller single-arm trial evaluating the safety and efficacy of GSK572 in 27 treatment-experienced patients, again mostly men, with pre-existing resistance to raltegravir (Isentress) and to any three antiretroviral drug classes (abstract MOAB0105). Participants in this study had more advanced HIV disease -- with a median CD4 cell count of 110 cells/mm3 and about 60% with a diagnosis of AIDS -- and they had been on ART for a median of 14 years and taken a median of 17 drugs.

All participants first received 50 mg once-daily GSK572 as "functional monotherapy" (i.e., the only active drug) for 10 days, then background regimens were optimized and treatment continued through week 24. Overall, 78% of study participants achieved viral load below 400 copies/mL by day 11, with a mean HIV RNA drop of 1.45 log. But response differed according to pre-existing resistance. Just 33% of people with a Q148 mutation plus at least one secondary mutation achieved virological response, compared with all patients with N155 and Y143 mutations. Again, GSK572 was generally well-tolerated with no serious drug-related adverse events.

In October, Shionogi-ViiV announced the start of the GSK57 Phase III development program, including the SPRING-2 trial enrolling treatment-naive participants and the SAILING study enrolling treatment-experienced patients.

Liz Highleyman (liz@black-rose.com) is a freelance medical writer based in San Francisco.




This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art61381.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.